September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
INTRAOCULAR SUSTAINED DELIVERY SYSTEM OF FLURBIPROFEN; EFFICACY AND PHARMACOKINETICS
Author Affiliations & Notes
  • Miltiadis K Tsilimbaris
    Medicine, University of Crete, Heraklion, Greece
  • Stella Blazaki
    Medicine, University of Crete, Heraklion, Greece
  • Chrysanthi Tsika
    Medicine, University of Crete, Heraklion, Greece
  • Konstantions Pachis
    Pharmacology, University of Patras, Patras, Greece
  • Irini Naoumidi
    Medicine, University of Crete, Heraklion, Greece
  • Christos Tsatsanis
    Medicine, University of Crete, Heraklion, Greece
  • Manolis Tzatzarakis
    Medicine, University of Crete, Heraklion, Greece
  • Sofia Antimisiaris
    Pharmacology, University of Patras, Patras, Greece
  • Footnotes
    Commercial Relationships   Miltiadis Tsilimbaris, None; Stella Blazaki, None; Chrysanthi Tsika, None; Konstantions Pachis, None; Irini Naoumidi, None; Christos Tsatsanis, None; Manolis Tzatzarakis, None; Sofia Antimisiaris, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Miltiadis K Tsilimbaris, Stella Blazaki, Chrysanthi Tsika, Konstantions Pachis, Irini Naoumidi, Christos Tsatsanis, Manolis Tzatzarakis, Sofia Antimisiaris; INTRAOCULAR SUSTAINED DELIVERY SYSTEM OF FLURBIPROFEN; EFFICACY AND PHARMACOKINETICS. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : The use of NSAIDS intraocularly remains a difficult task due to the short half-life time in the vitreous cavity.This study evaluates the intravitreal bioavailability and anti-inflammatory effects of sustained release flurbiprofen.

Methods : We evaluated a liposomal nanoformulation of flurbiprofen that is being explored in our laboratories. For pharmacokinetics we used two forms of flurbiprofen with concentrations of 7.66mg/ml and 15mg/ml. The kinetics of the slow release flurbiprofen were compared with the flurbiprofen alone. 3 eyes were analyzed per time point with means of HLPC/MS method. For efficacy, 100ng lipopolysaccharide (LPS) of E.coli were injected intravitreally to induce inflammation; the right eyes received 7.66mg/ml free flurbiprofen or 7.66mg/ml slow release flurbiprofen and the left eyes PBS. Clinical signs of inflammation were evaluated after 24h of LPS and aqueous humor was removed to determine the total cell count.

Results : No adverse events were observed concerning the pharmacokinetics of the drug. No signs of inflammation, hemorrhage or detachment were detected. The recovery of the method was 92.6%. The half-life of the slow release flurbiprofen solution of 7.66mg/ml and 15mg/ml was 24.75 hours and 23.90 hours respectively while the half-life of the flurbiprofen alone was 16.12 hours. The elimination constant rate (K) was 0.028, 0.029 and 0.043 respectively. Treatment with free flurbiprofen and slow release flurbiprofen reduced significantly total cell count by 51% and 80.5% respectively. Signs of inflammation were also reduced compared to control eyes.

Conclusions : We managed to extend the presence of the drug into the vitreous cavity. This is crucial for drugs such as the NSAIDs that have a very short intravitreal half-life time. Flurbiprofen demonstrated potent anti-inflammatory effects. However, the need for greater prolongation in the vitreous demands further experimentation with the system’s structure and the substance’s dosage.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×